Literature DB >> 8162054

Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.

M St-Louis1, B Leclerc, J Laine, M K Salo, C Holmberg, R M Tanguay.   

Abstract

Hereditary tyrosinemia type I is a metabolic disease caused by a deficiency of fumarylacetoacetate hydrolase (FAH, EC 3.7.1.2), the last enzyme in the catabolic pathway of tyrosine. The molecular basis of FAH deficiency was examined in five Finnish patients suffering from this severe metabolic disease. No immunoreactive FAH nor enzymatic activity were found in their liver. Direct sequencing of the 14 exons of the FAH gene showed a G to A transition, which predicts a change from tryptophan to a stop codon (TGG-->TGA) at position 262 (W262X). Four of the five patients examined were homozygous for the mutation. Allele specific oligonucleotide hybridization showed a predominance of the W262X mutation in Finland (9 of 10 alleles) and the absence of this mutant allele in patients from other parts of the world. The loss of a BsaJI restriction site in those patients may be used for diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162054     DOI: 10.1093/hmg/3.1.69

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

1.  A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays.

Authors:  T Pastinen; M Raitio; K Lindroos; P Tainola; L Peltonen; A C Syvänen
Journal:  Genome Res       Date:  2000-07       Impact factor: 9.043

Review 2.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

3.  The age of human mutation: genealogical and linkage disequilibrium analysis of the CLN5 mutation in the Finnish population.

Authors:  T Varilo; M Savukoski; R Norio; P Santavuori; L Peltonen; I Järvelä
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

4.  Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients.

Authors:  J Dubois; L Garel; H Patriquin; K Paradis; S Forget; D Filiatrault; A Grignon; P Russo; D St-Vil
Journal:  Pediatr Radiol       Date:  1996-12

5.  Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.

Authors:  J L Aponte; G A Sega; L J Hauser; M S Dhar; C M Withrow; D A Carpenter; E M Rinchik; C T Culiat; D K Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

6.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

7.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

8.  Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.

Authors:  H Rootwelt; E Brodtkorb; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

Review 9.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

10.  Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1.

Authors:  H Rootwelt; R Berger; G Gray; D A Kelly; T Coşkun; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.